东亚药业(605177) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue rose by 30.91% to CNY 189,641,637.80 year-on-year[5] - Net profit attributable to shareholders increased by 239.76% to CNY 24,540,005.70 compared to the same period last year[5] - Basic earnings per share increased by 175% to CNY 0.22 per share[5] - The company reported a significant increase in other non-current assets to ¥144,391,463.67 from ¥9,719,237.44, a substantial rise of 1,384.5%[19] - Total operating revenue for Q1 2021 reached ¥189,641,637.80, an increase of 30.9% compared to ¥144,861,994.62 in Q1 2020[26] - Net profit for Q1 2021 was ¥24,540,005.70, representing a significant increase of 240.5% from ¥7,222,815.25 in Q1 2020[27] - The company achieved an operating profit of ¥30,644,882.75 in Q1 2021, up from ¥10,051,321.84 in Q1 2020[27] Cash Flow and Liquidity - Net cash flow from operating activities reached CNY 46,869,087.68, a significant improvement from a negative cash flow of CNY -5,659,165.44 in the previous year[5] - Cash flow from operating activities in Q1 2021 was CNY 46,869,087.68, a turnaround from a negative cash flow of CNY -5,659,165.44 in Q1 2020[32] - The company incurred total operating cash outflows of CNY 103,480,008.44 in Q1 2021, compared to CNY 93,715,497.56 in Q1 2020, indicating a rise in operational expenses[32] - The net cash flow from financing activities in Q1 2021 was CNY -34,771,069.90, compared to CNY -13,913,065.85 in Q1 2020, indicating increased financing costs[33] - The ending balance of cash and cash equivalents was 48,683,277.29 CNY, down from 51,301,272.71 CNY in the previous year[37] Assets and Liabilities - Total assets increased by 2.77% to CNY 2,139,046,225.30 compared to the end of the previous year[5] - Total current assets as of March 31, 2021, amounted to ¥1,250,961,587.59, a decrease of 9.6% from ¥1,384,299,362.48 on December 31, 2020[18] - Total liabilities amounted to ¥384,940,270.81, compared to ¥351,790,713.93, marking an increase of 9.4%[20] - Total current liabilities increased to ¥347,516,177.31 from ¥313,742,341.39, a rise of 10.8%[19] - The company’s short-term borrowings decreased to zero from RMB 10,013,291.61, reflecting improved liquidity[13] Shareholder Information - The total number of shareholders reached 18,714 by the end of the reporting period[9] - The largest shareholder, Chi Zhengming, holds 41.48% of the shares[9] Research and Development - Research and development expenses increased by 37.50% to RMB 9,997,252.39, up from RMB 7,270,742.49 in the previous year, indicating a focus on innovation[14] - Research and development expenses for Q1 2021 totaled ¥9,997,252.39, an increase of 37.4% from ¥7,270,742.49 in Q1 2020[26] Operating Costs - Total operating costs for Q1 2021 were ¥160,904,935.12, up 16.5% from ¥138,095,696.05 in Q1 2020[26] - The company’s sales expenses increased by 140.54% to RMB 2,848,858.51, driven by higher hospitality and promotional costs[14]